• No results found

Original Article MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2

N/A
N/A
Protected

Academic year: 2020

Share "Original Article MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2"

Copied!
9
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Figure 1. The expression of miR-26b and EphA2 in HCC cell lines. A. qRT-PCR analysis revealed the expression level of miR-26b in eight HCC cell lines (HepG2, SMMC7721, Huh7, bel-7402, PLC, LM3, 97L and 97H) and human hepatocyte line L02
Figure 3. miR-26b inhibited cell proliferation of HCC. A. LM3 cells were transfected with EphA2 mimics
Figure 4. miR-26b inhibited invasion, and migration of HCC cells. A. The effects of miR-26b and EphA2 on cell inva-sion
Figure 5. miR-26b downregulates the expression of c-Myc and CyclinD1 by targeting EphA2

References

Related documents

ported by the suppression of both viability and axon the Drosophila Abelson tyrosine kinase in nerves and muscles: defects of Ptp69D mutants by selective expression of

Table 1 and 2 shows values the effect of administration of Garcinia kola seed powder for 21 days, initial and final on the haematological parameters of albino white rats..

this case, systematic error estimates obtained by taking the relative difference between the quadratic and logarithmic fits amounts to 6%, 5% and 3% for the unimproved,

WHAT’S KNOWN ON THIS SUBJECT: Data from pediatric trauma centers suggest that children with abusive abdominal trauma have higher mortality, longer hospitalizations, and

In addition to state science standards that promote cultural relevancy, each school district in Minnesota that has ten or more American Indian students can apply for Federal and State

Uncoupling protein (UCP) gene fam- ily involved in energy metabolism of body, and had significant effects on energy balance related traits, such as body weight resting metabolic

Three pivotal Phase III studies have demonstrated promising efficacy and a good safety and tolerability profile across doses of 50–200 mg/day in the adjunctive treatment of

Criteria used to compare the test and control groups: mean age of groups, number of inserted implants, group size, loading protocol (further details see 13 ), fi xed or